ClinicalTrials.govpublic full text
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
biliary tract cancer, rilvegostomig, durvalumab, bispecific antibody, pd-l1, tigit, initially unresectable, recurrent, intra-hepatic cholangiocarcinoma, extra-hepatic cholangiocarcinoma, gallbladder cancer, interventional
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 855296
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.